Kadimastem is a biotechnology company specializing in the commercialization of stem cell technology for curing Insulin Dependent Diabetes. Operating since January 2010, Kadimastem has developed technologies to use human embryonic stem cells for the derivation of pancreatic islet cells, which secrete insulin and related hormones in response to glucose. These cells will be used in transplantation treatments for potential cure of the disease. Kadimastem operates under a Licensing Agreement with Yeda, the commercial arm of the Weizmann Institute of Science. Independently, Kadimastem is developing cell based assays for screening of lead compounds for the treatment of neurological disorders, in particular myelin deficiencies.

Insulin-Dependent Diabetes (Type I and a subset of Type II) affects about 30 million people globally. A person who has Insulin-Dependent Diabetes must take insulin daily to survive the disease. The recently introduced beta cell transplantation from cadaveric donors ("Edmonton Protocol") suggests that a cell therapy approach can indeed cure Diabetes, freeing the patient from the need of frequent insulin injections. Once transplanted, the islet cells naturally monitor sugar levels and can regulate insulin levels by delivering the appropriate amounts needed to normalize blood glucose levels. However, a major challenge in donor cell transplantation is the collection of enough cells for the transplant as more than one donor pancreas are required per patient, while only 1,100 pancreas are available annually. As the need for islet beta cells surpasses the number of human donors available, the use of stem cell derived islets has become the leading strategy for curing Diabetes.